Immunosuppression in Patients with Chronic Hepatitis B. - Wikidata - wikimedia - TriplyDB

Immunosuppression in Patients with Chronic Hepatitis B.

Immunosuppression in Patients with Chronic Hepatitis B.

http://www.wikidata.org/entity/Q42764680

about

Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations Future Therapy for Hepatitis B Virus: Role of Immunomodulators Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.Effects of storage conditions on the stability of serum CD163, NGAL, HMGB1 and MIP2 Screening for hepatitis B in patients with lymphoma.IL-35: a potential therapeutic target for controlling hepatitis B virus infection.Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis.Hepatitis B immunopathogenesis and immunotherapy.Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.Hepatitis B reactivation in patients receiving targeted therapies.Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.Occult hepatitis B virus infection among people with a family history of chronic hepatitis B virus infection.Interleukin-35 Level Is Elevated in Patients with Chronic Hepatitis B Virus Infection.RFX1 participates in doxorubicin-induced hepatitis B virus reactivation.

P2860

Q26752690-45294413-EDBE-4879-B426-6DAD6563270C Q28078148-32A83941-F239-4B93-9A78-9C71A453C5E0 Q33872813-48C5A1AD-5C89-4837-8F59-385A5797B0B9 Q35741156-C7D673D8-E3E1-4C86-AC6F-48D989ADBFC8 Q36058282-BE45B7E9-3650-4683-922B-D2CF195A6ECC Q38283391-FC558210-8CC7-44BE-857C-103C52EA1AD2 Q38637664-293946E5-B171-4822-961D-0AA180F9BAB8 Q38773364-099B880D-007D-41E5-B5C3-10AFEAB9540D Q38810735-64361527-3591-4846-BA6D-A8EDA826604D Q39293427-A6E138D3-F9DF-47DF-9F4B-B63C93A91358 Q40172735-45B465A5-B5CF-4ADB-816F-783466AFAB7B Q41239881-D75AD7ED-AC33-4750-963E-7CC88A336D83 Q47553800-A2B2703C-4785-4A77-9873-11281857BD07 Q52618967-F5B922E8-B2A0-43E2-8A6B-F2E56BBCE3A4

P2860

Immunosuppression in Patients with Chronic Hepatitis B.

http://www.wikidata.org/entity/Q42764680

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Immunosuppression in Patients with Chronic Hepatitis B.

@en

Immunosuppression in Patients with Chronic Hepatitis B.

@nl

type

label

Immunosuppression in Patients with Chronic Hepatitis B.

@en

Immunosuppression in Patients with Chronic Hepatitis B.

@nl

prefLabel

Immunosuppression in Patients with Chronic Hepatitis B.

@en

Immunosuppression in Patients with Chronic Hepatitis B.

@nl

P1433

Q42764680-E6F1B6E5-C9FF-44F9-B2AC-6DB9F604C94B

P1476

Q42764680-0CA2B403-CAC5-4997-B6CA-E952C1C743B2

P2093

Q42764680-44844700-6B68-499F-811E-353179487620

Q42764680-B9B6C410-64A3-4596-9F97-845B8D8F699F

P2860

Q42764680-00B36DDB-8E3E-4966-B786-C9736BDF0C72

Q42764680-011E2C82-9AEF-4140-9B7C-4830849C9A6F

Q42764680-03C4FD42-A601-4D68-BE6C-BA180C7417B9

Q42764680-049C5291-27F7-4728-8912-259075722058

Q42764680-04A56A05-8B7D-4EC1-8CA4-AC298626A081

Q42764680-0B70B704-81F7-4AAE-AD3D-9ED13F63D3F4

Q42764680-0BB92745-98BC-427D-A1A4-6C07C3BC81C6

Q42764680-0D0933EB-EF1F-4ABE-BC7F-295CE1345E84

Q42764680-1742304B-E0F8-4A2B-8B98-0EB59959D68F

Q42764680-1A4A2A44-25B7-4BC6-8DFC-A65FF0CF6A4C

P2888

Q42764680-0F6D964C-6DA9-4D73-A38F-771FC30024F3

P304

Q42764680-F06582DB-8CD4-434D-B5AF-CDD19B73BF2A

P31

Q42764680-6DFAF9A0-BECE-4522-8E0B-AF412DA20903

P356

Q42764680-E1A316A5-FFB3-4D8B-8459-8C69B8CB5351

P478

Q42764680-760A44E2-6DC2-44CF-9D70-C3CDE203FF08

P50

Q42764680-0ABEE3C4-054B-4B60-9525-694C1CB8D848

P577

Q42764680-0F8FDC10-94DA-46DF-B584-B2487FA65FED

P5875

Q42764680-BB5DC48B-D813-46BF-B588-D2E641157CC9

P698

Q42764680-2CA2FE66-E689-435A-B1AE-31B01F379805

P921

Q42764680-B931EFAF-67ED-4E53-8B1B-1F9BB4031A0F

P932

Q42764680-8942148C-984D-4172-BCF4-F70B4E721537

P356

S11901-014-0238-2

P1433

Current hepatology reports

P1476

Immunosuppression in Patients with Chronic Hepatitis B

@en

P2093

Anil Seetharam

http://www.w3.org/2001/XMLSchema#string

Robert Perrillo

http://www.w3.org/2001/XMLSchema#string

P2860

Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation

Management of patients with hepatitis B who require immunosuppressive therapy

Burden of pediatric hepatitis C

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Hepatitis B "360".

Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.

P2888

s11901-014-0238-2

P304

235-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11901-014-0238-2

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264641493

http://www.w3.org/2001/XMLSchema#string

P698

25101233

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

4119588

http://www.w3.org/2001/XMLSchema#string